Insider buying last 90 days
No open-market insider purchases were filed for ATR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ATR insider filing, plotted on the chart in Gekko.Open ATR in Gekko
NYSE: ATR
AptarGroup (ATR) Stock Analysis & Forecast
Sep 28 close
$124.45+0.58 (+0.5%)
Gekko Brief
AptarGroup closed at $124.45 on 28 September 2026, +0.5% on the day. The price sits between the 50-day ($130.38) and 200-day ($126.75) moving averages, inside a 52-week range of $103.23 to $146.91. The GekkoIndex reads 63.7, in the Accumulation zone, down 6.8 points over five sessions. Gekko Fair Value is $149.63, so the price is 16.8% below it.
The next earnings report is due on 29 October 2026, 30 days away (before open). Over the last 8 reports the company beat the earnings estimate 8 times, with an average move of 4.5% across the report. Seasonally, the next 20 trading days from this point averaged +1.3% over the last 5 years, rising in 3 of them.
4 firms rate the stock: 3 buy, 1 hold and 0 sell, with a consensus target of $170.14. A typical daily move is about 1.8%, and a typical 20-day move about 3.9%. On the swing-trade checklist, 4 items read supportive and 0 read as a headwind.
Generated Sep 29, 2026 from the data above.
AptarGroup price vs fair value
Close $124.45200-day averageGekko Fair Value $149.63
AptarGroup quick facts
- Market cap
- $7.94B
- P/E ratio
- 22.6
- Forward P/E
- 19.8
- EPS, TTM
- $5.48
- Revenue, TTM
- $3.93B
- Profit margin
- 9.2%
- Dividend yield
- 1.53%
- Beta
- 0.38
- Volume
- 595,730 avg 438,948
- 1-year return
- −4.9%
- Typical daily move
- ±1.8%
- Typical 20-day move
- ±3.9%
- 50-day average
- $130.38
- 200-day average
- $126.75
- Next earnings
- Oct 29 before open
- Shares outstanding
- 63.58M
AptarGroup swing-trade checklist
AptarGroup scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $124.45 sits between the 50-day ($130.38) and 200-day ($126.75) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
63.7, Accumulation
Reading 63.7 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
16.8% below
Price is 16.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 30 days
Next report Oct 29, 2026, 30 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+1.3% on average
From this point in the calendar, the next 20 trading days averaged +1.3% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
AptarGroup stock chart and price history
AptarGroup closed at $124.45 on Sep 28, 2026, −4.9% over the past year, inside a 52-week range of $103.23 to $146.91.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −6.3%
- 3 months
- −0.7%
- 6 months
- +2.0%
- 1 year
- −4.9%
The full ATR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ATR in Gekko
Follow AptarGroup through every session
Put ATR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ATR in GekkoFree for 7 days. No credit card required.
About AptarGroup
AptarGroup designs and produces dispensing, sealing, and material science solutions used across beauty, personal care, home care, pharmaceutical, and food and beverage applications. Its offerings include pumps, closures, valves, and flow control components, and it is recognized for pharmaceutical items such as nasal allergy pumps, metered dose inhaler valves for asthma and COPD treatment, and elastomeric packaging for injectable drugs.
The company operates through three segments: Pharma, Beauty plus Home, and Food plus Beverage. The Pharma segment focuses on components for drug delivery and injectable packaging, while Beauty plus Home serves personal care and household product makers with pumps, closures, and sealing parts, along with decorative elements for beauty brands. Food plus Beverage supplies closures and dispensing parts for that market. Sales reach customers worldwide through an internal sales force along with independent representatives and distributors across Asia, Europe, Latin America, and North America. It also works with PureCycle Technologies on recycled polypropylene for dispensing products and with Sonmol on a digital platform for respiratory and other health-related therapies.
AptarGroup was founded in 1992 and is headquartered in Crystal Lake, Illinois. Its shares trade on the NYSE under the ticker ATR.
- Listed
- NYSE
- Sector
- Process industries
- Industry
- Containers/Packaging
- Website
- aptar.com
AptarGroup GekkoIndex: the smart money zone
AptarGroup’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 63.7, in the Accumulation zone, down 6.8 points over five sessions.
63.7Accumulation
Down 6.8 points over five sessions, from the Buying zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 62 | +0.6% | +1.2% | ||
| Accumulation (current zone) | 202 | −0.3% | −0.8% | ||
| Neutral | 358 | +0.1% | +0.3% | ||
| Distribution | 46 | 0.0% | −0.2% | ||
| Selling | 4 | Too few readings yet | |||
Average ATR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the ATR price, zone by zone.Track ATR in Gekko
Is AptarGroup stock overvalued? Gekko Fair Value
AptarGroup trades 16.8% below Gekko Fair Value of $149.63, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what AptarGroup shares are worth, recalculated every trading day.
$149.63
Gekko Fair Value, Sep 29, 2026
16.8% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open ATR in Gekko
AptarGroup insider and Congress trading
No open-market insider purchases were filed for AptarGroup, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ATR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ATR, plotted on the chart in Gekko.Open ATR in Gekko
Buybacks
AptarGroup has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $50.00M
- As a share of market cap
- 0.63%
- Trailing four quarters
- $365.0M
From company filings.
AptarGroup earnings: next date and track record
AptarGroup reports on Oct 29, 2026, before the open (30 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Oct 29, 2026
Expected before the open, 30 days away
- EPS estimate
- $1.46
- Revenue estimate
- $982.8M
8 of 8reports beat the EPS estimate
±4.5%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Feb 5, 2026 AI summary
- What they said
- Aptar reported strong Q4 and full-year 2025 top-line performance with reported sales up 14% to $963M and core sales up 5%. All three segments (Pharma, Beauty, Closures) delivered core sales growth; Pharma strength was driven by elastomeric components, systemic nasal drug delivery, and injectables (including GLP-1-related demand), while Beauty saw double-digit core growth partly aided by tooling sales and holiday demand, and Closures showed solid volume growth. Adjusted EBITDA was $191M with a margin of 19.8%, down from 23% a year ago due to unfavorable product mix, higher-than-expected production costs in Beauty & Closures, and a large year-over-year decline in emergency medicine (NARCAN/destocking). Management emphasized productivity initiatives, back-office centralization, a rigorous productivity roadmap, and a strong balance sheet to fund growth and capital returns. They disclosed an approximately $65M full-year headwind from emergency medicine destocking (front-loaded in H1 ~70/30 split H1/H2), expect injectables to grow high-single to low-double digits steady-state, and reaffirm a multi-year view of being within long-term margin targets. Management acknowledged operational disruptions (supplier fire, an anodization environmental compliance action, backlog of maintenance at a Closures site) but characterized most items as transitory and expressed confidence margins will improve sequentially with stronger H2 performance. Capital allocation remains growth-focused with flexibility for buybacks under a refreshed $600M authorization.
- Guidance
- No formal numeric guidance was given. Management provided the following forward-looking commentary: - Expect injectables to grow in the high-single to low-double-digit range on a steady-state basis. - Emergency medicine (NARCAN) represents an approximately $65M full-year headwind, with roughly 70% of the impact in H1 and 30% in H2. - Margins are expected to be significantly more robust in the back half of 2026 versus the first half; full-year results are expected to be within the company's long-term target range. - Management did not provide quarter-by-quarter EPS guidance but expects sequential improvement in Beauty and Closures margins starting in Q1 and stronger H2 performance overall. - Capital allocation: continue to invest for growth while returning capital to shareholders; $600M buyback authorization provides flexibility.
- Risks flagged
- Operational disruptions (unscheduled maintenance backlog at a Closures site; equipment downtime; supplier fire leading to temporary worse pricing/quality); product mix headwinds (notably a destocking-driven decline in emergency medicine/NARCAN causing an estimated $65M full-year headwind, heavier in H1); environmental compliance-related costs at a Beauty anodization plant; potential tax and interest rate cost increases; exposure to variability in consumer demand (holiday events, cold/cough season) and timing of new drug adoption for pipeline launches; execution risk on productivity initiatives though management reports historical progress.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Feb 5, 2026 | $1.25 est $1.24 | $962.7M est $878.6M | +3.9% |
| Oct 30, 2025 | $1.62 est $1.57 | $961.1M est $880.2M | −6.7% |
| Jul 31, 2025 | $1.66 est $1.58 | $966.0M est $959.0M | −9.8% |
| May 1, 2025 | $1.20 est $1.16 | $887.3M est $898.6M | +1.4% |
| Feb 6, 2025 | $1.52 est $1.26 | $848.1M est $852.3M | −9.6% |
| Oct 24, 2024 | $1.49 est $1.42 | $909.3M est $862.0M | +0.8% |
| Jul 25, 2024 | $1.37 est $1.36 | $910.1M est $933.2M | +1.7% |
| Apr 25, 2024 | $1.26 est $1.15 | $915.4M est $931.5M | +2.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
AptarGroup stock forecast and analyst price targets
Analysts’ average 12-month price target for AptarGroup is $170.14, +36.7% from the last close, from 4 firms rating the stock in the last 90 days.
$170.14consensus 12-month target, +36.7% from the last close
Now $124.45Avg $170.14
Low $155High $172
Each firm’s latest rating in the last 90 days: 4 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 20 | Bank of America Securities | $172 | +38.2% |
| Aug 3 | Wells Fargo | $155 | +24.5% |
| Jul 31 | Bank of America Securities | — | — |
| Jul 31 | William Blair | — | — |
| Jul 31 | William Blair | — | — |
−0.8%average 20-day move after past Accumulation readings
+1.3%average move over the next 20 trading days in the last 5 years
±1.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
AptarGroup seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, AptarGroup averaged +1.3% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.9% | 4 of 5 |
| Next 10 trading days | +0.8% | 3 of 5 |
| Next 15 trading days | +1.5% | 2 of 5 |
| Next 20 trading days | +1.3% | 3 of 5 |
| Next 30 trading days | +2.4% | 4 of 5 |
For scale, ATR’s typical 20-trading-day move in either direction is about 3.9%.
AptarGroup market cap and key statistics
AptarGroup’s market cap is $7.94B, with a P/E ratio of 22.6 and revenue of $3.93B over the last twelve months.
Valuation
- Market cap
- $7.94B
- P/E ratio
- 22.6
- Forward P/E
- 19.8
- EPS, TTM
- $5.48
- Gekko Fair Value
- $149.63
Trading
- Volume
- 595,730
- Avg volume, 20 days
- 438,948
- 52-week high
- $146.91
- 52-week low
- $103.23
- Shares outstanding
- 63.58M
Financials
- Revenue, TTM
- $3.93B
- Profit margin
- 9.2%
- Return on equity
- 13.5%
- Quarterly earnings growth, YoY
- −18.6%
Risk and income
- Beta
- 0.38
- Typical daily move
- ±1.8%
- Typical 20-day move
- ±3.9%
- Dividend yield
- 1.53%
AptarGroup stock news this week
Coverage of AptarGroup this week reads neutral: 2 positive, 4 neutral and 2 negative headlines.
- Zacks Industry Outlook Highlights Avery Dennison, AptarGroup and Karat PackagingTradingView, Sep 28
- AptarGroup, Inc. (ATR) stock price, news, quote and historyYahoo Finance Singapore, Sep 25
- AptarGroup, Inc. (ATR) Stock Price, News, Quote & HistoryYahoo! Finance Canada, Sep 23
- AptarGroup Number of Employees 2026 | Employee Count & Headcount DataRevelio Labs, Sep 23
- Russian decree affects small AptarGroup (NYSE: ATR) unitStock Titan, Sep 22
- AptarGroup, Inc. (ATR) Stock Analysis: Exploring A 36.73% Potential UpsideDirectorsTalk Interviews, Sep 22
AptarGroup peers
AptarGroup’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| SWSmurfit WestRock | Neutral | 8.9% above |
| PKGPackaging Corporation of America | Accumulation | 8.2% above |
| AMCRAmcor | Accumulation | 37.2% below |
| BALLBall | Buying | 7.5% above |
| CCKCrown | Accumulation | 41.4% below |
| OCOwens Corning | Accumulation | 7.7% below |
A peer links to its own page where one exists.
AptarGroup stock FAQ
What is AptarGroup’s market cap?
AptarGroup’s market cap is $7.94B at the Sep 28, 2026 close of $124.45, with 63.58M shares outstanding. The shares trade on a P/E ratio of 22.6.
What is the AptarGroup stock forecast?
The consensus analyst 12-month price target for AptarGroup is $170.14, +36.7% from the last close. Of the 4 firms that rated the stock in the last 90 days, 3 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is AptarGroup stock overvalued or undervalued?
On Gekko’s estimate AptarGroup is undervalued: the Sep 28, 2026 close of $124.45 is 16.8% below Gekko Fair Value of $149.63. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does AptarGroup report earnings next?
AptarGroup is expected to report on Oct 29, 2026, before the market opens (30 days away). Analysts expect earnings of $1.46 per share on revenue of $982.8M. AptarGroup beat the earnings estimate in 8 of its last 8 reports, moving 4.5% on average across the report.
What is AptarGroup’s 52-week high and low?
AptarGroup’s 52-week high is $146.91 and its 52-week low is $103.23; it closed at $124.45 on Sep 28, 2026, −4.9% over the past year. Over the last five years the shares peaked at $178.03 on Nov 11, 2024.
Is AptarGroup stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See AptarGroup the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.